Dr. Coveler on Replacing 5-FU With NUC-3373 in mCRC
Andrew Coveler, MD, discusses the potential clinical implications of positive data with NUC-3373 in metastatic colorectal cancer.
Dr. Coveler on the Toxicity Profile of NUC-3373 in Metastatic CRC
Andrew Coveler, MD, discusses the toxicity profile of NUC-3373 in metastatic colorectal cancer.
Dr. Coveler on the Rationale to Evaluate NUC-3373 in Metastatic CRC
Andrew Coveler, MD, discusses the rationale to evaluate NUC-3373 in metastatic colorectal cancer.
Dr. Coveler on SEA-CD40 Combo in Metastatic Pancreatic Ductal Adenocarcinoma
Andrew Coveler, MD, discusses the investigational CD40-directed monoclonal antibody SEA-CD40 in combination with gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma.
Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD
Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers
Dr Ramdial on Gemcitabine/Clofarabine/Busulfan for Lymphoma Stem Cell Transplant
Retrospective Analysis Shows Post-HCT Survival Benefits With Orca-T Vs PTCy in Hematologic Malignancies
2 Commerce Drive Cranbury, NJ 08512